# SpyGlass Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spyglass-pharma

- Industry: Pharmaceuticals
- Headquarters: Aliso Viejo, US
- Website: www.spyglasspharma.com
- Total disclosed funding: $115M
- Latest round: Series D (May 30, 2025)
- Investors on record: 7

## About

Based in California, US, and established in 2019, SpyGlass Pharma, Inc. provides therapies for the treatment of chronic ophthalmic diseases. The company was co-founded by Malik Y. Kahook and Glenn Sussman. As of 2023, the company is headed by its CEO Patrick Mooney. In February 2026, SpyGlass Pharma, Inc. raised USD 150 million in an IPO, selling 9.4 million shares at USD 16 per share on Nasdaq under the ticker symbol "SGP". The company offers SpyGlass Drug Delivery Platform which is a controlled-release drug delivery platform for all cataract surgeons, that consists of a single-piece, hydrophobic acrylic IOL and two drug-eluting pads. It is implanted along with the SpyGlass IOL into the capsular bag through a standard cataract surgical technique. The company will use the February 2026 funding for drug research and development and commercial rollout.

## Funding rounds

- Series D, May 30, 2025, $75M — New Enterprise Associates, Gilde Healthcare, RA Capital Management, Sands Capital Alternatives, Vertex Ventures HC, Samsara BioCapital, Vensana Capital
- Series C, Jul 6, 2023, $40M — New Enterprise Associates, RA Capital Management, Vertex Ventures HC, Samsara BioCapital, Vensana Capital

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series C, Series D
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C, Series D
- Vertex Ventures HC (https://capitalatlas.ai/funds/vertex-ventures-hc) — Series C, Series D
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series C, Series D
- Vensana Capital (https://capitalatlas.ai/funds/vensana-capital) — Series C, Series D
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series D
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series D